Astrajeneka Pharma India Limited said on Monday that the company received a warning letter from the National Stock Exchange of India on 7 February.
“It was observed that the company is in non-approval with the provisions of Lodr’s regulation 18 (2) (b), as only one independent director attended the audit committee meeting held on 27 May 2024,” an exchange filing Was attached by the company.
Under Regulation of SEBI Listing Regulations under 18 (2) (b )- Quorum will be either two members for the Audit Committee meeting or one third of the Audit Committee members, whichever is more, with at least two independent directors . The letter states, “The above non-transportation is seen seriously on your behalf.”
The NSE has advised the company to be careful in future, taking care to take care of caution and to avoid the recurrence of such laps so that proper compliance with the exchange circular can be ensured. “In the future, any disaster will be seen seriously and appropriate action will be initiated,” said this.
Additionally, the drug manufacturer has been advised by the NSE to a warning letter before its board of directors and to avoid such laps before corrective measures.
The benchmark Nifty 50 index declined 0.81% on the shares of Astrazneca Pharma India, compared to a decline of 0.76%, decreased by 0.76% on the NSE. The stock has increased by 31.9% in the last 12 months.
(Tagstotransite) Astrazeneca Pharma India Limited (T) NSE
